Beat Neuenschwander

TL;DR: This manuscript reviews several methods for historical borrowing, illustrating how key parameters in each method affect borrowing behavior, and then, compares these methods on the basis of mean square error, power and type I error.

TL;DR: The Bayesian approach to finding the maximum-tolerated dose in phase I cancer trials is discussed and a comparison with the continual reassessment method (CRM) is performed with data from an actual trial and a simulation study.

TL;DR: This work derives a Bayesian meta-analytic-predictive prior from historical data, which is then combined with the new data, and proposes two- or three-component mixtures of standard priors, which allow for good approximations and, for the one-parameter exponential family, straightforward posterior calculations.

TL;DR: The proposed approach is attractive for nonconfirmatory trials, but under certain circumstances extensions to the confirmatory setting could be envisaged as well.

TL;DR: Recommendations on how to improve dose ranging in clinical development are put forward, including, but not limited to, the use of adaptive dose-ranging methods.